A transdermal patch comprising: a microneedle in a protruding position, protruding from the transdermal patch; and immobilised functional molecules; wherein a fluid path is provided between the distal tip of the microneedle and the immobilised functional molecules; and the functional molecules are selected to interact with selected target molecules so as to convert or trap said target molecules. The device intends to dynamically curb the postprandial insulin spike offering an unprecedented therapeutic effect for diabetes and obesity with significant benefits in morbidity and without strict diet. The device offers unprecedented phenylketonuria management that removes the burden of strict diet. The device offers easy removal of autoantibodies, low density lipoprotein and other pathogenic molecules. The device can be used in any disorder that requires enzymatic replacement or elimination of pathogenic molecules via biochemical conversion or trapping.

According to some embodiments, a system may treat blood outside the body of a patient. The system may include one or more pumps configured to pump blood in a fluid flow path at a collective rate over 4 liters per minute. The system may include one or more heat exchangers operable to heat at least a portion of the blood to a temperature of at least 42 degrees Celsius and to allow the blood to cool one or more degrees following heating. The system may include one or more albumin dialysis modules configured to perform albumin dialysis on at least a portion of the blood at least after the one or more heat exchangers allow the blood to cool one or more degrees.

A system, device, and autologous method for treating blood. Blood is extracted from a patient. The blood is tested to determine one or more pathogens and conditions of the blood. One or more catalysts are automatically added into the blood of the patient. The one or more catalysts are activated utilizing the one or more emitters configured to interact with the one or more catalysts in the blood create treated blood. One or more additives are added into the threated blood. The treated blood is reinjected into the patient.

A gas delivery system is provided. The gas delivery system includes a pump operable to receive blood from a patient. A gas transfer unit is in fluid communication with the pump and operable to receive the blood from the pump and deliver a therapeutic amount of xenon gas to the blood. A patient connector withdraws and/or infuses the blood into the patient.

The invention relates to a device for treating an individual suffering from cardiac or circulatory arrest or from a stroke, comprising a blood withdrawal device (BE) that is applied to the individual (P), an analysis unit (BA) which is directly or indirectly connected to the blood withdrawal device for detecting a blood analysis result (BAE) providing at least one characteristic of the blood, directly or indirectly connected to a blood return device (BR) that is applied to the individual (P) and is designed to deliver a substance to the individual via the return device (BR).

According to some embodiments, a system may treat blood outside the body of a patient. The system may include one or more pumps configured to draw blood from a patient into a fluid flow path at a rate, for example, of 5-7 liters per minute. The system may include one or more heat exchangers coupled to the fluid flow path and configured to heat the blood, for example, to a temperature above 42 degrees Celsius and below 43.2 degrees Celsius.

The present invention relates to a device for the treatment of blood comprising a solid phase on which a polypeptide is immobilized which is suitable for the inactivation of free nucleic acids. Suitable polypeptides are, for example, deoxyribonucleases, ribonucleases, DNA methyltransferases or cytosine deaminases. The invention further comprises the use of such devices for the treatment of patients suffering from chronic kidney failure, cancer or lupus erythematosus, as well as methods and systems for the treatment of blood, wherein free nucleic acids are inactivated outside the body.

The invention relates to a treatment device (100) which is designed for extracorporeal blood treatment of blood of a subject (2) for an immunotolerance enhancement of the subject (2), comprising at least one container (10) which has an interior (11) for receiving a blood sample (1) of blood of the subject (2) and an exchange device (20) designed to supply and/or discharge the blood sample (1) into or out of the interior (11) of the container (10) and comprising a cell exposure device (30) which is positioned in the container (10) and has biological cell material (31) with surface molecules, said cell material being arranged in the interior (11) of the container (10) for a material interaction with the blood sample (1), including a reaction of endogenous immune cells in the blood with the surface molecules of the cell material. The invention also relates to a kit for extracorporeal blood treatment and to a method for operating the treatment device.

Cerebrospinal fluid (CSF) and other fluid amelioration systems completely or partially implantable within a mammalian subject and associated methods include a substrate and an agent for amelioration of a toxic biomolecule present in the CSF or fluid, wherein the agent is disposed on or within the substrate.

An embodiment provides a method for treating a body fluid of a patient with Covid-19, including: removing the body fluid from a patient, wherein the body fluid comprises a Covid-19 targeted pathogenic antigen (TPA); applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with the Covid-19 targeted pathogenic antigen in the body fluid to form an antibody-TPA complex, wherein the antibody comprises a radiofrequency absorption enhancer forming an antibody-radio frequency enhancing moiety-virion complex (ARFVC); removing the ARFVC from the body fluid using a radiofrequency source; and returning the body fluid to the patient. Other aspects are described and claimed.